[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity

Rhea-AI Filing Summary

ANI Pharmaceuticals officer Krista Davis reported a sale of 1,000 shares of ANIP common stock on 09/19/2025 at a price of $98.04 per share. The sale was executed under a Rule 10b5-1 trading plan adopted August 23, 2024. After the transaction, the reporting person beneficially owns 60,186 shares, held directly. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person and records the transaction as a routine, preplanned disposition under the company insider trading plan.

Positive

• Sale executed under Rule 10b5-1 plan, indicating the transaction was preauthorized
• Reporting compliance: Form 4 filed with transaction details and signature by attorney-in-fact
• Substantial remaining ownership: 60,186 shares beneficially owned after the sale

Negative

• Disposition of shares: 1,000 shares were sold at $98.04, representing a reduction in direct holdings

Insights

Financial Analyst

TL;DR: Routine insider sale under a 10b5-1 plan; modest disposition relative to total holdings, no new material disclosure.

The reporting person sold 1,000 shares at $98.04 under a Rule 10b5-1 plan adopted 08/23/2024, indicating the trade was pre-authorized and not opportunistic. Post-sale beneficial ownership is 60,186 shares, reported as direct. For investors, this Form 4 documents compliance and a small liquidity event rather than a strategic change; there is no indication of acceleration, option exercise, or derivative activity in this filing.

Corporate Governance Expert

TL;DR: Governance process followed: sale via an established 10b5-1 plan and timely Form 4 filing.

The filing appropriately discloses the transaction date, price, and that the sale was executed pursuant to a 10b5-1 trading plan adopted 08/23/2024, which supports the reporting person's defense against insider trading claims. The Form 4 is signed by an attorney-in-fact, showing delegated execution. No amendments or derivative holdings are reported. This is consistent with transparent insider reporting practices and routine compliance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Krista

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF HR OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		S(1)		1,000	D	$98.04	60,186	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2024.

Remarks:

	/s/ Krista Davis, by attorney-in-fact Meredith W. Cook	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ANI Pharmaceuticals insider Krista Davis report on Form 4 (ANIP)?

The Form 4 reports a sale of 1,000 shares of ANIP common stock on 09/19/2025 at $98.04 per share.

Was the trade by Krista Davis part of a 10b5-1 plan for ANIP?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 08/23/2024.

How many ANIP shares does Krista Davis beneficially own after the reported transaction?

After the reported sale, the Form 4 shows beneficial ownership of 60,186 shares, held directly.

Did the Form 4 disclose any derivative or option transactions for ANIP?

No. The filing contains only a non-derivative sale of common stock and shows no derivative securities reported.

Who signed the Form 4 for Krista Davis?

The Form 4 is signed on behalf of Krista Davis by an attorney-in-fact, Meredith W. Cook, dated 09/22/2025.